Strategies for management of "difficult to treat" Gram negative infections: Focus on Pseudomonas aeruginosa;Strategie terapeutiche per la gestione delle infezioni da Gram negativi "difficili": Focus su Pseudomonas aeruginosa

Infezioni in Medicina

Volumn 15, Issue SUPPL. 2, 2007, Pages 20-26

  Bassetti, Matteo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Nosocomial infections; Pseudomonas aeruginosa

Indexed keywords

BETA LACTAM; CEFTOBIPROLE; DORIPENEM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BACTEREMIA; BURN; CATHETERIZATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; COMMUNITY CARE; CONFERENCE PAPER; CYSTIC FIBROSIS; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; MORTALITY; NEUTROPENIA; PSEUDOMONAS AERUGINOSA; SEPSIS; SKIN INFECTION; SURGICAL WOUND; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; META-ANALYSIS AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 36049046764     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Nicoletti G., Schito G., Fadda G. Bacterial isolates from severe infections and their antibiotic susceptibility patterns in Italy: a nationwide study in the hospital setting. J. Chemother. 18, 6, 589-602, 2006.
2. Gaynes R., Edwards J.R. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41, 6, 848-854, 2005.
3. Nicastri E., Petrosillo N., Martini L., Larosa M., Gesu G.P., Ippolito G. Prevalence of nosocomial infections in 15 Italian hospitals: first point prevalance study for the INF-NOS project. Infection. 31 Suppl 2, 10-15, 2003.
4. Trouillet J.L., Chastre J., Vuagnat A. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am. J. Respir. Crit. Care Med. 157, 2, 531-539, 1998.
5. Putinati S., Ballerin L., Piattella M., Ritrovato L., Zabini F., Potena A. La polmonite acquisita in comunità nell'anziano. Eziologia, aspetti clinici e fattori prognostici. Minerva Pneumologica. 413, 99, 2004.
6. Eller J., Ede A., Schaberg T., Niederman M.S., Mauch H., Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest. 113, 6, 1542-1548, 1998.
7. Alzarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med. 22, 5, 387-394, 1996.
8. Rello J., Gallego M., Mariscal D., Sonora R., Valles J. The value of routine microbial investigation in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 156, 1, 196-200, 1997.
9. Luna C.M., Vujacich P., Niederman M.S., et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest. 111, 3, 676-685, 1997.
10. Kollef M.H., Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest. 113, 2, 412-420, 1998.
11. Sanchez-Nieto J.M., Torres A., Garcia-Cordoba F. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: a pilot study. Am. J. Respir. Crit. Care Med. 157, 2, 371-376, 1998.
12. Ruiz M., Torres A., Ewig S., et al. oninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome. Am. J. Respir. Crit. Care Med. 162,1, 119-125, 2000.
13. Dupont H., Mentec H., Sollet J.P., Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med. 27, 2, 355-362.
14. Kollef M.H. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin. Infect. Dis. 31 Suppl 4, S131-S138, 2000.
15. Kang C.I., Kim S.H., Kim H.B. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin. Infect. Dis. 37, 6, 745-751, 2003.
16. American Thoracic Society. Infectious Diseases Society of America.Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171, 4, 388-416, 2005.
17. Chamot E., Boffi E.l., Amari E., Rohner P., Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 47, 9, 2756-2764, 2003.
18. Micek S.T., Lloyd A.E., Ritchie D.J., Reichley R.M., Fraser V.J., Kollef M.H. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob. Agents Chemother. 49, 4, 1306-1311, 2005.
19. Safdar N., Handelsman J., Maki D.G. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect. Dis. 4, 8, 519-527, 2004.
20. Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst. Rev. (1), CD003344, 2006.
21. Bliziotis I.A., Samonis G., Vardakas K.Z., Chrysanthopoulou S., Falagas M.E. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin. Infect. Dis. 41, 2, 149-158, 2005.
22. Shorr A.F., Susla G.B., Kollef M.H. Quinolones for treatment of nosocomial pneumonia: a meta-analysis. Clin. Infect. Dis. 40 Suppl 2, S115-S122, 2005.
23. Tennenberg A.M., Davis N.B., Wu S.C., Kahn J. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience. Curr. Med. Res. Opin. 22, 5, 843-850, 2006.
24. Karlowsky J.A., Jones M.E., Thornsberry C., Evangelista A.T., Yee Y.C., Sahm D.F. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies. Clin. Infect. Dis. 40 Suppl 2, S89-S98, 2005.
25. Lister R.D., Welter D.J. Levofloxacin Imipenem combination prevents the emergence of resistance among clinical isolates of P. aeruginosa. Clinical Infecious Disease 40, S105-14, 2005.
26. Bassetti M., Righi E., Rosso R. Efficacy of the combination of levofloxacin plus ceftazidime in the treatment of hospital-acquired pneumonia in the intensive care unit. Int. J. Antimicrob. Agents. 28, 6, 582-585, 2006.
27. Pea F., Di Qual E., Cusenza A., Brollo L., Baldassarre M., Furlanut M. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin. Pharmacokinet. 42, 6, 589-598, 2003.
28. Shorr A.F., Zadeikis N., Jackson W.L., Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial. Clin. Infect. Dis. 40 (Suppl 2), S123-S129, 2005.
29. Levin P.D., Fowler R.A., Guest C., Sibbald W.J., Kiss A., Simor A.E. Risk factors associated with resistance to ciprofloxacin in clinical bacterial isolates from intensive care unit patients. Infect. Control. Hosp. Epidemiol. 28, 3, 331-336, 2007.
30. Chastre J., Wolff M., Fagon J.Y. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290, 19, 2588-2598, 2003.